Core Viewpoint - Cinda Biologics is expected to report strong performance in the fiscal year 2025, achieving a net profit of 834 million yuan for the first time, with total revenue reaching 13 billion yuan, representing a year-on-year growth of 38% [1] Financial Performance - Total revenue for Cinda Biologics is projected to be 13 billion yuan, reflecting a year-on-year increase of 38% [1] - Product sales are anticipated to reach 11.9 billion yuan, marking a year-on-year growth of 45% [1] - The company is set to record its first annual net profit of 834 million yuan [1] Investment Outlook - The strong product line innovation capability and global development potential of Cinda Biologics support its transformation into a global biopharmaceutical company [1] - The investment rating for Cinda Biologics is maintained at "Buy," with the target price slightly increased from 110.62 HKD to 113.86 HKD [1]
大行评级丨招银国际：微升信达生物目标价至113.86港元，维持“买入”评级